

Wisconsin Pharmacy Cost Study Committee

May 28, 2020



Call to Order/Review of Agenda

Item 1

Technical Orientation

- Committee members/speakers:
 - Thank you for joining early to ensure audio quality!
 - Please mute/unmute your own line to speak
 - Chat function may be used only for technology help requests
- Audience phone lines should remain muted. There is no opportunity for public comment at this meeting. Audience attendees with lines causing substantial feedback may be removed from the call.

Approval of Minutes

Item 2

Analytics Proposal Status

Item 3

Third Party Analytics Proposal on Hold

- Workgroup determined that Medicaid privacy rules limited analytic capability in a way that could not be overcome by third parties
- In-house staff can analyze remaining data well enough to offer recommendations

Pooled/Complementary Purchasing Options

Item 4

Common Drugs Analysis

Generic Name Group	ETF						Medicaid (DHS)			DOC		
	Total Cost	Total Rebates	Total Cost net of Rebates	Total Scripts	Cost per Script	Cost net of Rebates per Script	Net Paid Amount	Total Scripts	Net Paid per Script	Purchase Dollars	Ship Qty	Package Price
ADALIMUMAB	\$18,550,655.83	\$4,056,893.62	\$14,493,762.21	3,181	\$5,831.71	\$4,556.35	\$1,798,822.60	6,071	\$296.30	\$2,244,744.43	463	\$4,848.26
ALBUTEROL SULFATE	\$1,085,528.17	\$589,685.77	\$495,842.40	16,793	\$64.64	\$29.53	\$6,647,556.06	188,469	\$35.27	\$307,369.91	7,563	\$40.64
BUPRENORPHINE HCL-NALOXONE HCL	\$7,362.77	\$1,411.83	\$5,950.94	26	\$283.18	\$228.88	\$3,485,622.90	52,926	\$65.86			
ETANERCEPT	\$6,159,607.13	\$1,347,423.19	\$4,812,183.94	1,204	\$5,115.95	\$3,996.83	\$7,504,418.80	Not Available	Not Available	\$396,292.08	82	\$4,832.83
FLUTICASONE-SALMETEROL	\$3,322,858.66	\$2,253,132.77	\$1,069,725.89	7,063	\$470.46	\$151.45	\$4,033,180.31	33,542	\$120.24			
GLATIRAMER ACETATE	\$1,157,711.43	\$89,556.89	\$1,068,154.54	393	\$2,945.83	\$2,717.95	\$2,465,874.00	Not Available	Not Available	\$76,595.18	14	\$5,471.08
INSULIN GLARGINE	\$4,875,671.33	\$2,268,362.68	\$2,607,308.65	8,308	\$586.86	\$313.83	\$8,831,963.50	48,903	\$180.60	\$441,152.17	3,019	\$146.13
INSULIN LISPRO	\$25,246.22	\$0.00	\$25,246.22	45	\$561.03	\$561.03				\$43,085.68	209	\$206.15
LISDEXAMFETAMINE DIMESYLATE	\$2,083,592.62	\$344,606.42	\$1,738,986.20	6,635	\$314.03	\$262.09	\$3,564,582.20	100,989	\$35.30			
LURASIDONE HCL	\$630,081.42	\$53,130.69	\$576,950.73	475	\$1,326.49	\$1,214.63				\$214,042.87	215	\$995.55
METHYLPHENIDATE HCL	\$1,419,678.19	\$0.00	\$1,419,678.19	10,005	\$141.90	\$141.90						
PREGABALIN	\$1,697,361.71	\$126,801.41	\$1,570,560.30	2,469	\$687.47	\$636.11	\$0.00	32,122	\$0.00	\$311,434.46	475	\$655.65
RIVAROXABAN	\$2,187,651.17	\$536,005.62	\$1,651,645.55	3,192	\$685.35	\$517.43	\$0.00	Not Available	\$0.00	\$48,256.14	119	\$405.51

Incurred 1/1/19 – 6/30/19

Only matched data included for DOC table

Medicaid data notes:

- Net Paid Amount is post-rebate
- Orange-shaded data updated on 5/12/20
- Top 10 by Net Paid and by Prescription reported

Focus 1: Humira (adalimumab)

	ETF		Medicaid		DOC	
	Total Scripts	Net Cost/Script	Total Scripts	Net Cost/Script	Total Scripts	Cost/Script
Adalimumab	3,181	\$4,556	6,071	\$296	463	\$4,848

- Common across all three programs
- High cost, high volume
- Combed volume, in addition to drug's patent status, may present opportunities for savings for ETF & DOC (also possibly Medicaid supplemental rebates)
- Options:
 - RFB for drug-specific pooled purchasing arrangement
 - Add-on to existing ETF contract for DOC, Medicaid

Focus 2: Insulin

	ETF		Medicaid		DOC	
	Total Scripts	Net Cost/Script	Total Scripts	Net Cost/Script	Total Scripts	Cost/Script
Insulin glargine	8,308	\$314	48,903	\$181	3,019	\$146

- Common across all programs; also, known statewide area of need
- Options:
 - **Combined purchasing** could provide similar benefits, though competition in class and open Medicaid formulary may limit negotiation leverage
 - Agencies could also **align formularies** (DOC/ETF) with Medicaid preferred drug list (PDL) to indirectly leverage volume
 - Propose **public health purchasing agreement** for insulin to Governor’s Task Force

Focus 3: Albuterol Sulfate

	ETF		Medicaid		DOC	
	Total Scripts	Net Cost/Script	Total Scripts	Net Cost/Script	Total Scripts	Cost/Script
Albuterol sulfate	16,793	\$30	188,469	\$35	7,563	\$41

- Similar options as Insulin

Opportunities

- Possible Savings
 - \$1.8M for DOC on Humira if reduced to ETF's price
 - \$1.4M for ETF on insulin if reduced to DOC's price
 - \$84K for DOC on albuterol if reduced to ETF's price
 - Additional savings possible if better prices can be negotiated with volume

Risks

- Removing drugs from contracts might risk other discounts
- Savings values are relatively small and should be weighed versus the cost to administer
- Current DOC savings estimates do not include changes from 340B pricing, so DOC savings potential may be overstated

Questions

- Medicaid data still cannot be shared at a granular level, and so data questions remain
 - Ex: rebate values reducing some drugs to \$0.00
 - Ex: ETF's apparent better price on albuterol sulfate despite Medicaid Best Price rules
- Contract ownership amongst independent agencies would still need to be determined

Discussion

Reports

Item 5

Next Steps/Adjourn



Questions?

Thank you



[wi_etf](#)



[etf.wi.gov](#)



ETF E-mail Updates



608-266-3285
1-877-533-5020